

1 **SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality**

2
3 Jesse Fajnzylber^{1*}, James Regan^{1*}, Kendyll Coxen^{1*}, Heather Corry^{1*}, Colline Wong¹, Alexandra
4 Rosenthal¹, Daniel Worrall², Francoise Gigue³, Alicja Piechocka-Trocha², Caroline Atyeo²,
5 Stephanie Fischinger², Andrew Chan³, Keith T. Flaherty³, Kathryn Hall³, Michael Dougan³,
6 Edward T. Ryan³, Elizabeth Gillespie¹, Rida Chishti¹, Yijia Li¹, Nikolaus Jilg^{1,3}, Dusan
7 Hanidziar³, Rebecca M. Baron¹, Lindsey Baden¹, Athe M. Tsibris¹, Katrina A. Armstrong³,
8 Daniel R. Kuritzkes¹, Galit Alter^{2,3}, Bruce D. Walker^{2,3,4}, Xu Yu^{2,3}, and Jonathan Z. Li¹, for the
9 Massachusetts Consortium for Pathogen Readiness

10

- 11 1. Brigham and Women's Hospital, Harvard Medical School, Boston, MA
12 2. Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA
13 3. Massachusetts General Hospital, Harvard Medical School, Boston, MA
14 4. Howard Hughes Medical Institute, Chevy Chase, MD

15

16 *Contributed equally to this article

17 A list of the Massachusetts Consortium for Pathogen Readiness contributors is provided in the
18 Supplementary Appendix

19

20

21 **Corresponding Author:**

22 Jonathan Li, MD

23 Brigham and Women's Hospital

24 65 Landsdowne Street, Rm 421

25 Cambridge, MA 02139

26 jli@bwh.harvard.edu

27

28 **Short title:** Clinical impact of SARS-CoV-2 viremia

29

30 **Keywords:** COVID-19, SARS-CoV-2, mortality, hospitalized, respiratory tract, plasma viral

31 load

32

33 **Financial support:**

34 This study was supported in part by the Massachusetts Consortium for Pathogen Readiness

35 through grants from the Evergrande Fund, Mark and Lisa Schwartz (to Drs. Li and Yu), Nancy

36 Zimmerman (to Dr. Alter), NIH grants U01AI106701 (to Dr. Li), by the Harvard University

37 Center for AIDS Research (NIAID 5P30AI060354), 3R37AI080289 (to Dr. Alter), CDC grant

38 U01CK000490 (to Dr. Ryan), and the SAMANA Kay MGH Scholar program (to Dr. Alter).

39

40 **Disclosures:**

41 Dr. Li has consulted for Abbvie and Jan Biotech. Dr. Alter is the founder of Seromyx Inc.

42

43

44 **ABSTRACT**

45 The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely

46 undefined in coronavirus disease 2019 (COVID-19). We quantified SARS-CoV-2 viral load

47 from participants with a diverse range of COVID-19 severity, including those requiring
48 hospitalization, outpatients with mild disease, and individuals with resolved infection. SARS-
49 CoV-2 plasma RNA was detected in 27% of hospitalized participants and 13% of outpatients
50 diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, higher
51 prevalence of detectable SARS-CoV-2 plasma viral load was associated with worse respiratory
52 disease severity, lower absolute lymphocyte counts, and increased markers of inflammation,
53 including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, were
54 associated with increased risk of mortality. SARS-CoV-2 viral load may aid in the risk
55 stratification of patients with COVID-19 and its role in disease pathogenesis should be further
56 explored.

57

58 INTRODUCTION

59 In coronavirus disease 2019 (COVID-19), the relationship between levels of viral replication and
60 disease severity remains unclear. In prior analyses of the SARS-CoV-1 outbreak, viral load
61 within the nasopharynx was associated with worsened disease severity and increased mortality^{1,2}.
62 However, it is also clear that there are significant differences between SARS-CoV-1 and 2,
63 including differences in the temporal nature of viral shedding^{3,4}, transmissibility⁵, epidemiology⁶,
64 and clinical manifestations^{7,8}. Additional studies are needed to determine whether the degree of
65 SARS-CoV-2 viral load within the respiratory tract or other compartments may predict disease
66 outcomes.

67 The need for additional SARS-CoV-2 viral studies is not only limited to respiratory
68 specimens but extends to the blood. Respiratory failure is the primary cause of death in patients
69 with COVID-19, but complications arising from a hyperactive immune response and vascular
70 damage are also prominently featured both in the pulmonary and extrapulmonary systems⁹⁻¹³. In
71 addition, there is a suggestion that detectable plasma viremia using a qualitative qPCR assay may
72 correlate with disease severity¹⁴, although studies to date have been hampered by the lack of viral
73 load quantification. Together, these findings suggest the importance of systemic SARS-CoV-2
74 viral circulation, but little is known about the prevalence and magnitude of plasma viremia in
75 predicting COVID-19 outcomes. In this study, we quantified SARS-CoV-2 viral load from the
76 respiratory tract, plasma and urine of participants with a diverse range of COVID-19 severity,
77 including individuals requiring hospitalization, symptomatic non-hospitalized participants, and
78 those recovered from COVID-19 disease.

79 RESULTS

80 Participant characteristics and SARS-CoV-2 viral loads

81 We enrolled 88 hospitalized participants with COVID-19, 94 symptomatic individuals who were
82 evaluated in a respiratory infection clinic, of whom 16 were diagnosed with COVID-19 by
83 standard clinical testing of nasopharyngeal swabs, and 53 participants diagnosed with COVID-19
84 who had symptomatically recovered. Table 1 shows baseline demographic information, disease
85 severity and hospital outcomes. Hospitalized participants were significantly older than both
86 symptomatic outpatients and individuals recovered from COVID-19 (Kruskal-Wallis $P < 0.001$).
87 Participants recruited in the outpatient setting had the shortest time between the start of
88 symptoms and the time of sample collection (median 5 days) compared to hospitalized
89 individuals (median 13 days) and recovered participants (median 27 days).

90 We report SARS-CoV-2 viral load analysis both as a continuous variable and analyzed as
91 a categorical variable (detectable versus undetectable) given that only qualitative commercial
92 qPCR testing is available for clinical care. Amongst hospitalized individuals, the majority still
93 had detectable SARS-CoV-2 RNA at the time of initial sample collection, including 50% with
94 detectable SARS-CoV-2 RNA by nasopharyngeal swab, 67% by oropharyngeal swab, and 85%
95 by sputum testing. We also performed SARS-CoV-2 viral load testing from specimens outside of
96 the respiratory tract and found that 27% of participants had detectable SARS-CoV-2 plasma
97 viremia and 10% had detectable viral RNA in the urine (Fig 1). In those with detectable plasma
98 viremia, the median viral load was 2.4 \log_{10} RNA copies/mL (range 1.8 – 3.8 \log_{10} RNA
99 copies/mL), which was significantly lower than that detected in sputum (median 4.4 \log_{10} RNA
100 copies/mL, range 1.8 – 9.0 \log_{10} RNA copies/mL, Wilcoxon signed-rank $P < 0.001$).

101 Levels of SARS-CoV-2 viral load were significantly correlated between each of the
102 different respiratory specimen types (nasopharyngeal vs oropharyngeal Spearman $r = 0.34$, $P =$
103 0.03 ; nasopharyngeal vs sputum $r = 0.39$, $P = 0.03$, oropharyngeal vs sputum $r = 0.56$, $P = 0.001$,
104 Supplemental Fig 1). Plasma viral load was modestly associated with both nasopharyngeal ($r =$
105 0.32 , $P = 0.02$) and sputum viral loads ($r = 0.36$, $P = 0.049$), but not significantly associated with
106 oropharyngeal viral loads. There was no significant association between urine viral load and viral
107 loads from any other sample types.

108

109 **SARS-CoV-2 viral load is associated with disease severity and laboratory abnormalities**

110 Detectable plasma viremia was generally associated with increased disease severity amongst
111 hospitalized participants as 44% of those on a ventilator had detectable viremia compared to 19%
112 of those receiving supplemental oxygen by nasal cannula and 0% of individuals not requiring
113 supplemental oxygen ($\chi^2 P = 0.006$, Fig 1b). Two of the 16 (13%) COVID-19 diagnosed
114 outpatients were found to also have detectable SARS-CoV-2 plasma viremia, compared to none
115 of the 74 outpatients with negative clinical nasopharyngeal testing for SARS-CoV-2 RNA and
116 none of the 53 recovered individuals who had previously been diagnosed with COVID-19. None
117 of the 18 plasma samples from intensive care unit participants collected in the pre-COVID era
118 were found to have detectable plasma SARS-CoV-2 RNA.

119 In hospitalized participants, higher plasma viral loads were significantly associated with
120 several markers of inflammation and disease severity, including lower absolute lymphocyte
121 counts (Spearman $r = -0.31$, $P = 0.008$), and higher levels of both CRP ($r = 0.40$, $P < 0.001$) and
122 IL-6 ($r = 0.50$, $P < 0.001$). Significant associations were also detected between nasopharyngeal
123 and sputum viral loads and these three markers (Fig 2a). When analyzed as a categorical

124 variable, individuals with detectable plasma, nasopharyngeal or sputum viral loads had
125 significantly lower absolute lymphocyte counts, and higher CRP and IL-6 levels compared to
126 those without detectable plasma viremia (Fig 2b-d). Plasma, nasopharyngeal and/or
127 oropharyngeal viral loads were also significantly associated with increased levels of the
128 inflammatory cytokines IL-8, IP-10, MCP1, IFN- γ , and IL-1RA (Fig 2a).

129

130 **SARS-CoV-2 viral loads and mortality risk**

131 Compared to individuals who were discharged from the hospital, those who eventually died had
132 significantly higher levels of plasma viremia at the time of initial sampling (median plasma viral
133 load 1.0 vs 2.0 log₁₀ RNA copies/mL, $P = 0.009$, Fig 3a), which occurred a median 11 days
134 before death. For hospitalized individuals with initial detectable viremia, 32% died vs 8% of
135 those without initial viremia (OR 5.5, $P = 0.02$, Fig 3e). We performed a sensitivity analysis to
136 assess whether plasma viremia may also predict mortality in those with the most severe disease.
137 For participants who were on ventilatory support at the time of initial sample collection, 43% of
138 those with detectable plasma viremia died compared to 17% of those without detectable plasma
139 viremia, although this comparison did not reach statistical significance (OR 3.8, $P = 0.11$). We
140 also performed an analysis in older participants as the majority of participants who died were at
141 least 70 years old. In those ≥ 70 years old with initial plasma viremia, 6 of 7 died (86%) vs 2 of 9
142 (22%) without initial viremia (OR 21, $P = 0.02$). Levels of SARS-CoV-2 viral load in respiratory
143 secretions were also higher in those who eventually died (Fig 3b-d), although the presence or
144 absence of detectable respiratory secretion viral RNA were not significantly associated with
145 increased risk of death (Fig 3f-h). Logistic regression analysis was also performed with viral

146 loads as a continuous variable and plasma, oropharyngeal and sputum viral loads were all
147 associated with increased risk of death (Supplementary Table 1).

148 A subset of hospitalized participants had longitudinal viral load measurements. Levels of
149 plasma and respiratory viral loads declined from the first and second sampling time points in
150 almost all participants, regardless of eventual participant outcome (Fig 4).

151 **DISCUSSION**

152 We report a comprehensive analysis of SARS-CoV-2 respiratory tract, plasma, and urine viral
153 loads of 235 participants who were either hospitalized with COVID-19, evaluated as
154 symptomatic outpatients, or had recovered from COVID-19 disease. The results show a
155 relatively high prevalence of SARS-CoV-2 plasma viremia in hospitalized individuals with
156 severe disease, but plasma viremia was also detected in symptomatic non-hospitalized
157 participants. Levels of SARS-CoV-2 viremia was also associated with markers of inflammation
158 and disease severity, including low lymphocyte counts, and elevated CRP and IL-6 levels. To
159 our knowledge, this is also the first report that SARS-CoV-2 viral loads, especially detectable
160 plasma viremia, predicted the risk of death.

161 In contrast to prior reports suggesting that the SARS-CoV-2 viral infection is largely
162 confined to the respiratory and gastrointestinal tracts^{15,16}, we were able to detect plasma viremia
163 in a substantial proportion of both hospitalized and non-hospitalized participants. The prevalence
164 of SARS-CoV-2 plasma viremia was lower than that found in respiratory secretions, but
165 detectable plasma viremia had a clear relationship with concurrent clinical disease severity,
166 lower absolute lymphocyte count, higher levels of inflammation and increased risk of death.
167 Across the spectrum of viral infections, the extent of viral load has been a predictor of disease
168 severity and progression, including for HIV^{17,18}, Ebola¹⁹, influenza and other non-COVID-19
169 respiratory viral infections²⁰⁻²². The detection of plasma viral load has been described for both
170 SARS-CoV-1^{23,24} and SARS-CoV-2¹⁴, but its role in pathogenesis and ability to predict clinical
171 outcomes remains unresolved. To our knowledge, this is the first report demonstrating that
172 SARS-CoV-2 is frequently detectable in plasma and that detectable viral load, both in plasma
173 and the respiratory tract, are associated with increased disease severity and mortality. Therefore,

174 the detection and quantification of viral RNA levels may aid in the risk stratification of patients
175 hospitalized with COVID-19. The association between SARS-CoV-2 viral load with levels of
176 CRP and IL-6 results also suggest that active viral infection could contribute to the
177 hyperinflammatory state that is a hallmark of severe COVID-19²⁵. However, the causes of
178 inflammation in COVID-19 could be multifactorial, especially as a subset of participants had
179 elevated inflammatory markers without detectable plasma viremia. Additional studies are needed
180 to determine whether antiviral treatment may effectively interrupt this pathway and whether
181 levels of SARS-CoV-2 viral load could stratify patients into individuals who are more likely to
182 benefit from an antiviral agent versus those with isolated immune dysregulation who may benefit
183 more from an anti-inflammatory or immune-modifying agent¹³.

184 The source for the plasma viremia is still not fully defined and could reflect spillage from
185 the pulmonary tissue into the vasculature, but there is evidence that SARS-CoV-2 can also
186 directly infect endothelial cells. Angiotensin-converting enzyme 2 (ACE2) is the primary
187 receptor for SARS-CoV-2 and can be found on both arterial and venous endothelial cells²⁶ and
188 other perivascular cells²⁷. Tissue studies have also revealed evidence of endothelitis with
189 perivascular inflammation¹² and the extrapulmonary spread of SARS-CoV-2 to other organs²⁸.
190 While additional infectivity studies are needed to confirm that plasma viremia represents
191 infectious virions, these previously published support the concept that COVID-19 should be
192 considered more than an isolated respiratory tract infection and that endothelial infection and
193 systemic circulation of infectious SARS-CoV-2 virions may be contributing to the increasing
194 reports of extrapulmonary and micro- and macrovascular complications of COVID-19 that are
195 often disproportionate to the degree of disease severity^{9-12,29-32}.

196 There is an intense search for biomarkers of COVID-19 disease progression that could
197 accelerate early-phase clinical studies of antiviral agents against SARS-CoV-2. There has been
198 an expectation that respiratory tract viral shedding could serve as such a surrogate biomarker, but
199 it is unclear if such assumptions are accurate. An example is the reported clinical benefit of
200 remdesivir³³ despite the lack of evidence that remdesivir significantly reduces respiratory tract
201 viral loads³⁴. We found only modest correlations between respiratory tract viral loads and those
202 of the plasma. This highlights the need for additional studies to assess whether these anatomic
203 compartments may serve as distinct sites of viral replication and whether antiviral medications
204 might have differential effects on viral respiratory tract shedding versus plasma viremia.

205 Our study has a few notable limitations. First, sputum samples were obtained for only a
206 subset of participants as many participants were unable to generate a sample. While sputum
207 samples had the highest frequency of SARS-CoV-2 detection, this finding demonstrates a
208 potential limitation in their use as a reliable diagnostic modality. Our longitudinal analysis of
209 viral load changes was limited to a subset of participants due to limits on the frequency of blood
210 draws for hospitalized individuals and early discharges in those with relatively mild disease.
211 Additional studies of plasma viral load dynamics early in the course of disease are needed.

212 In summary, we report that SARS-CoV-2 plasma viremia is commonly detected in
213 hospitalized individuals but can also be detected in symptomatic non-hospitalized outpatients
214 diagnosed with COVID-19. SARS-CoV-2 viral loads, especially within plasma, are associated
215 with systemic inflammation, disease progression, and increased risk of death. The role of SARS-
216 CoV-2 as a mediator of vascular and extrapulmonary COVID-19 disease manifestations should
217 be further explored.

218

219

220 **Acknowledgements**

221 We would like to thank the participants of this trial and the dedicated clinical staff who cared for
222 them. We appreciate the support of the Ragon Institute of MGH, MIT and Harvard, the
223 Massachusetts General Hospital Translational and Clinical Research Center, the Brigham and
224 Women's Hospital Center for Clinical Investigation and the Partners Biobank.

225

226 **Appendix.** Massachusetts Consortium for Pathogen Readiness (MassCPR) contributors:

227 Betelihem A. (Betty) Abayneh³, Patrick Allen³, Diane Antille³, Alejandro Balazs^{2,3}, Julia Bals^{2,3},
228 Max Barbash^{2,3}, Yannic Bartsch^{2,3}, Julie Boucau^{2,3}, Siobhan Boyce³, Joan Braley³, Karen
229 Branch³, Katherine Broderick³, Julia Carney³, Josh Chevalier^{2,3}, Manish C Choudhary¹, Navin
230 Chowdhury^{2,3}, Trevor Cordwell¹, George Daley⁴, Susan Davidson³, Michael Desjardins¹, Lauren
231 Donahue¹, David Drew³, Kevin Einkauf^{2,3}, Sampson Elizabeth¹, Ashley Elliman³, Behzad
232 Etemad¹, Jon Fallon^{2,3}, Liz Fedirko^{2,3}, Kelsey Finn^{2,3}, Jeanne Flannery³, Pamela Forde³, Pilar
233 Garcia-Broncano^{2,3}, Elise Gettings³, David Golan⁴, Kirsten Goodman¹, Amanda Griffin³, Sheila
234 Grimmel³, Kathleen Grinke³, Ciputra Adijaya Hartana^{2,3}, Meg Healy³, Howard Heller^{3,4},
235 Deborah Henault³, Grace Holland³, Chenyang Jiang^{2,3}, Hannah Jordan¹, Paulina Kaplonek^{2,3},
236 Elizabeth W. Karlson¹, Marshall Karpell^{2,3}, Chantal Kayitesi³, Evan C. Lam^{2,3}, Vlasta LaValle³,
237 Kristina Lefteri^{2,3}, Xiaodong Lian^{2,3}, Mathias Lichterfeld^{1,3}, Daniel Lingwood^{2,3}, Hang Liu^{2,3},
238 Jinqing Liu^{2,3}, Kell Lopez¹, Yuting Lu³, Sarah Luthern³, Ngoc L. Ly^{2,3}, Maureen MacGowan¹,
239 Karen Magispoc¹, Jordan Marchewka³, Brittani Martino³, Roseann McNamara³, Ashlin
240 Michell^{2,3}, Ilan Millstrom^{2,3}, Noah Miranda^{2,3}, Christian Nambu³, Susan Nelson³, Marjorie
241 Noone³, Lewis Novack¹, Claire O'Callaghan^{2,3}, Christine Ommerborn³, Matthew Osborn^{2,3}, Lois
242 Chris Pacheco³, Nicole Phan³, Shiv Pillai^{2,3}, Falisha A. Porto³, Yelizaveta Rassadkina^{2,3},

243 Alexandra Reissis^{2,3}, Francis Ruzicka^{2,3}, Kyra Seiger^{2,3}, Kathleen Selleck³, Libera Sessa^{2,3},
244 Arlene Sharpe⁴, Christianne Sharr^{2,3}, Sally Shin^{2,3}, Nishant Singh^{2,3}, Sue Slaughenhaupt³,
245 Kimberly Smith Sheppard³, Weiwei Sun^{2,3}, Xiaoming Sun^{2,3}, Elizabeth (Lizzie) Suschana³,
246 Opeyemi Talabi¹, Hannah Ticheli^{2,3}, Scott T. Weiss¹, Vivine Wilson³, Alex Zhu^{2,3}

247

- 248 1. Brigham and Women's Hospital, Harvard Medical School, Boston, MA
249 2. Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA
250 3. Massachusetts General Hospital, Harvard Medical School, Boston, MA
251 4. Harvard Medical School, Boston, MA

252

253

254

255 **METHODS**

256 **Participant enrollment and sample collection**

257 We enrolled hospitalized and non-hospitalized participants with COVID-19 in a longitudinal
258 sample collection study at two academic medical centers. Blood was collected from consented
259 hospitalized participants diagnosed with COVID-19, non-hospitalized symptomatic individuals
260 seeking care at a respiratory infection clinic, and participants who had recovered from known
261 COVID-19 disease. Nasopharyngeal swabs, oropharyngeal swabs, sputum, and urine were also
262 collected from hospitalized participants. Nasopharyngeal swabs and oropharyngeal swabs were
263 collected in 3 mL of phosphate buffered saline (PBS). A subset of hospitalized participants had
264 longitudinal samples collected. Plasma obtained from a cohort of individuals in the intensive
265 care unit from the pre-COVID-19 era were used as a comparator group³⁵. Each participant's
266 electronic medical record was reviewed to determine the oxygenation status (room air, on
267 oxygen by nasal cannula, or requiring ventilator support), demographics, comorbidities and the
268 outcome of the hospitalization (discharge or death). This study was approved by the Partners
269 Institutional Review Board.

270

271 **Markers of inflammation and disease severity**

272 Levels of C-reactive protein (CRP) and absolute lymphocyte count were recorded from the
273 electronic medical record. Thirty-five additional markers of inflammation were evaluated in
274 plasma by the Luminex xMAP assay (ThermoFisher): EGF, Eotaxin, FGF-basic, G-CSF, GM-
275 CSF, HGF, IFN- α , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
276 IL-9, IL-10, IL-12 (p40/p70) IL-13, IL-15, IL-17A, IL-17F, IL-22, IP-10, MCP-1, MIG, MIP-1 α ,
277 MIP-1 β , RANTES, TNF- α , and VEGF.

278 **SARS-CoV-2 Viral Load Quantification**

279 Levels of SARS-CoV-2 viral load were quantified using the US CDC 2019-nCoV_N1 primers
280 and probe set³⁶. Virions were pelleted from respiratory secretions, swab fluids, plasma, or urine
281 by centrifugation at approximately 21,000 x g for 2 hours at 4°C. The supernatant was removed
282 and 750 µL of TRIzol-LS™ Reagent (ThermoFisher) was added to the pellets and then incubated
283 on ice. Following incubation, 200 µL of chloroform (MilliporeSigma) was added and vortexed.
284 The mixtures were separated by centrifugation at 21,000 x g for 15 minutes at 4°C, and
285 subsequently the aqueous layer was removed and treated with an equal volume of isopropanol
286 (Sigma). GlycoBlue™ Coprecipitant (ThermoFisher) and 100 µL 3M Sodium Acetate (Life
287 Technologies) were added to each sample and incubated on dry ice until frozen. RNA was
288 pelleted by centrifugation at 21,000 x g for 45 minutes at 4°C. The supernatant was discarded
289 and the RNA was washed with cold 70% ethanol. The RNA was resuspended in DEPC-treated
290 water (ThermoFisher).

291 Each reaction contained extracted RNA, 1X TaqPath™ 1-Step RT-qPCR Master Mix,
292 CG (ThermoFisher), the CDC N1 forward and reverse primers, and probe³⁶. Viral copy numbers
293 were quantified using N1 qPCR standards in 16-fold dilutions to generate a standard curve. The
294 assay was run in triplicate for each sample and two non-template control (NTC) wells were
295 included as negative controls. Quantification of the Importin-8 (IPO8) housekeeping gene RNA
296 level was performed to determine the quality of respiratory sample collection. An internal virion
297 control (RCAS) was spiked into each sample and quantified to determine the efficiency of RNA
298 extraction and qPCR amplification³⁷.

299

300 **Statistical analyses**

301 Levels of SARS-CoV-2 viral load at the time of initial hospital collection were compared by site
302 of sampling, disease severity and hospital outcome. SARS-CoV-2 viral load analysis was
303 performed both as continuous variables with non-parametric rank-based testing and as a
304 categorical variable (detectable vs undetectable) with Fisher's exact and X^2 tests given the
305 qualitative nature of current commercial qPCR tests. SARS-CoV-2 viral loads below 40 RNA
306 copies/mL were categorized as undetectable and set at $1.0 \log_{10}$ RNA copies/mL. For the subset
307 of participants with repeated sampling, the sign test was used to assess viral load change between
308 the first and second time point. Correlation analysis was performed using Spearman rank-based
309 testing. In the correlation analysis between the soluble inflammatory markers and viral load, a P-
310 value <0.01 between a marker and any of the viral load measurements was the threshold to
311 include that marker in the reported results. Logistic regression and other statistical analyses were
312 performed using GraphPad Prism 8 and SAS software, version 9.4. Only univariate analysis was
313 performed due to the available sample size, but we did perform sensitivity analysis for plasma
314 viral load effects based on disease severity and age.
315

316 **References**

- 317 1 Cheng, V. C. *et al.* Viral replication in the nasopharynx is associated with diarrhea in patients
318 with severe acute respiratory syndrome. *Clin Infect Dis* **38**, 467-475, doi:10.1086/382681 (2004).
- 319 2 Hung, I. F. *et al.* Viral loads in clinical specimens and SARS manifestations. *Emerg Infect Dis* **10**,
320 1550-1557, doi:10.3201/eid1009.040058 (2004).
- 321 3 To, K. K. *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples and
322 serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
323 *Lancet Infect Dis*, doi:10.1016/S1473-3099(20)30196-1 (2020).
- 324 4 Xu, K. *et al.* Factors associated with prolonged viral RNA shedding in patients with COVID-19. *Clin*
325 *Infect Dis*, doi:10.1093/cid/ciaa351 (2020).
- 326 5 He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*,
327 doi:10.1038/s41591-020-0869-5 (2020).
- 328 6 Wu, J. T. *et al.* Estimating clinical severity of COVID-19 from the transmission dynamics in
329 Wuhan, China. *Nat Med* **26**, 506-510, doi:10.1038/s41591-020-0822-7 (2020).
- 330 7 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*,
331 doi:10.1056/NEJMoa2002032 (2020).
- 332 8 Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel
333 coronavirus (SARS-CoV2). *Science*, doi:10.1126/science.abb3221 (2020).
- 334 9 Oxley, T. J. *et al.* Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J*
335 *Med*, doi:10.1056/NEJMc2009787 (2020).
- 336 10 Menter, T. *et al.* Post-mortem examination of COVID19 patients reveals diffuse alveolar damage
337 with severe capillary congestion and variegated findings of lungs and other organs suggesting
338 vascular dysfunction. *Histopathology*, doi:10.1111/his.14134 (2020).

- 339 11 Ackermann, M. *et al.* Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in
340 Covid-19. *N Engl J Med*, doi:10.1056/NEJMoa2015432 (2020).
- 341 12 Varga, Z. *et al.* Endothelial cell infection and endotheliitis in COVID-19. *Lancet*,
342 doi:10.1016/S0140-6736(20)30937-5 (2020).
- 343 13 Giamarellos-Bourboulis, E. J. *et al.* Complex Immune Dysregulation in COVID-19 Patients with
344 Severe Respiratory Failure. *Cell Host Microbe*, doi:10.1016/j.chom.2020.04.009 (2020).
- 345 14 Chen, X. *et al.* Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with
346 drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. *Clin Infect Dis*,
347 doi:10.1093/cid/ciaa449 (2020).
- 348 15 Wang, W. *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA*,
349 doi:10.1001/jama.2020.3786 (2020).
- 350 16 Wolfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*,
351 doi:10.1038/s41586-020-2196-x (2020).
- 352 17 Mellors, J. W. *et al.* Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
353 *Science* **272**, 1167-1170 (1996).
- 354 18 Saag, M. S. *et al.* HIV viral load markers in clinical practice. *Nat Med* **2**, 625-629,
355 doi:10.1038/nm0696-625 (1996).
- 356 19 Towner, J. S. *et al.* Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an
357 outbreak setting and assessment of patient viral load as a predictor of outcome. *J Virol* **78**, 4330-
358 4341, doi:10.1128/jvi.78.8.4330-4341.2004 (2004).
- 359 20 Vos, L. M. *et al.* Lower respiratory tract infection in the community: associations between viral
360 aetiology and illness course. *Clin Microbiol Infect*, doi:10.1016/j.cmi.2020.03.023 (2020).


- 361 21 Li, C. C. *et al.* Correlation of pandemic (H1N1) 2009 viral load with disease severity and
362 prolonged viral shedding in children. *Emerg Infect Dis* **16**, 1265-1272,
363 doi:10.3201/eid1608.091918 (2010).
- 364 22 Lee, N. *et al.* Viral loads and duration of viral shedding in adult patients hospitalized with
365 influenza. *J Infect Dis* **200**, 492-500, doi:10.1086/600383 (2009).
- 366 23 Grant, P. R. *et al.* Detection of SARS coronavirus in plasma by real-time RT-PCR. *N Engl J Med*
367 **349**, 2468-2469, doi:10.1056/NEJM200312183492522 (2003).
- 368 24 Wang, W. K. *et al.* Detection of severe acute respiratory syndrome coronavirus RNA in plasma
369 during the course of infection. *J Clin Microbiol* **43**, 962-965, doi:10.1128/JCM.43.2.962-965.2005
370 (2005).
- 371 25 Blanco-Melo, D. *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-
372 19. *Cell* **181**, 1036-1045 e1039, doi:10.1016/j.cell.2020.04.026 (2020).
- 373 26 Hamming, I. *et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS
374 coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* **203**, 631-637,
375 doi:10.1002/path.1570 (2004).
- 376 27 Chen, L., Li, X., Chen, M., Feng, Y. & Xiong, C. The ACE2 expression in human heart indicates new
377 potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc Res*
378 **116**, 1097-1100, doi:10.1093/cvr/cvaa078 (2020).
- 379 28 Puellas, V. G. *et al.* Multiorgan and Renal Tropism of SARS-CoV-2. *N Engl J Med*,
380 doi:10.1056/NEJMc2011400 (2020).
- 381 29 Spiezia, L. *et al.* COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive
382 Care Unit for Acute Respiratory Failure. *Thromb Haemost*, doi:10.1055/s-0040-1710018 (2020).
- 383 30 Ranucci, M. *et al.* The procoagulant pattern of patients with COVID-19 acute respiratory distress
384 syndrome. *J Thromb Haemost*, doi:10.1111/jth.14854 (2020).

- 385 31 Bikdeli, B. *et al.* COVID-19 and Thrombotic or Thromboembolic Disease: Implications for
386 Prevention, Antithrombotic Therapy, and Follow-up. *J Am Coll Cardiol*,
387 doi:10.1016/j.jacc.2020.04.031 (2020).
- 388 32 Zhang, Y. *et al.* Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *N Engl*
389 *J Med* **382**, e38, doi:10.1056/NEJMc2007575 (2020).
- 390 33 Beigel, J. H. *et al.* Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med*,
391 doi:10.1056/NEJMoa2007764 (2020).
- 392 34 Wang, Y. *et al.* Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-
393 controlled, multicentre trial. *Lancet* **395**, 1569-1578, doi:10.1016/S0140-6736(20)31022-9
394 (2020).
- 395 35 Boudreault, F. *et al.* Zinc deficiency primes the lung for ventilator-induced injury. *JCI Insight* **2**,
396 doi:10.1172/jci.insight.86507 (2017).
- 397 36 (Centers for Disease Control and Prevention (CDC), Accessed April, 2020).
- 398 37 Palmer, S. *et al.* New real-time reverse transcriptase-initiated PCR assay with single-copy
399 sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol* **41**, 4531-
400 4536 (2003).
- 401

Table 1. Demographics and Clinical Characteristics of Participants at Baseline

Characteristic	Hospitalized (N=88)	Symptomatic Non- Hospitalized (N=90)	Recovered (N=53)
Female sex, %	38%	62%	65%
Age, median years [Q1,Q3]	57 [43,68]	48 [31,59]	33 [29,42]
Ethnicity			
Caucasian	35%	79%	81%
Black/African American	15%	8%	6%
Hispanic/Latino	38%	3%	6%
Other	12%	10%	8%
Comorbidities			
Hypertension	53%	22%	2%
Chronic Lung Disease	18%	30%	2%
Diabetes	40%	11%	2%
BMI			
<25	20%	35%	62%
25-29.99	35%	24%	24%
≥30	45%	40%	14%
Days Between Symptom Onset and Initial Sample Collection, median [Q1,Q3]	13 [10,18]	5 [2,15]	27 [20, 34]
Oxygenation Status at Time of Enrollment			
Room Air	15%		
Nasal Cannula	37%		
Ventilator	48%		
Hospitalization Status			
% discharged	85%		
% mortality	13%		

A



B




Figure 1. SARS-CoV-2 viral loads at the time of initial sampling. (A) Levels of SARS-CoV-2 viral loads at the time of initial sampling and across specimen types. The percent of samples with detectable viral loads are shown at the bottom. (B) (A) Percent of participants with detectable plasma SARS-CoV-2 viral load by hospitalization status and disease severity. Symptomatic nasopharyngeal swab positive (NP+) and negative (NP-) individuals were evaluated at an outpatient respiratory infection clinic. Recovered individuals included participants who had previously been diagnosed with COVID-19, but whose symptoms have since resolved.

A




Figure 2. SARS-CoV-2 viral load is associated with markers of inflammation and disease severity. (A) Heat map of Spearman correlation values with bold numbers indicating $P < 0.05$. Absolute lymphocyte count, CRP, and IL-6 levels in hospitalized participants with and without detectable plasma (B), nasopharyngeal (C), and sputum (D) viral loads. NP, nasopharyngeal; VL, viral load.




B

Absolute Lymphocyte Count

CRP




IL-6

Plasma






C

NP



D

Sputum






Figure 3. SARS-CoV-2 viral load and risk of death. (A-D) Participants who died had higher initial viral loads compared to those who survived to discharge. (E-H) Percent of participants who eventually died categorized by detectable viral load and disease severity at the time of initial sampling.






Figure 4. Longitudinal viral load measurements of samples obtained from plasma (A-B), nasopharyngeal swab (C-D), oropharyngeal swab (E-F), or Sputum (G-H). Red dots and lines show viral loads in those who died. Sign test p-values showing significant changes over time are reported in an analysis of viral loads at the first and second available time points (TP).



Supplemental Figure 1. Correlation of respiratory tract and plasma viral loads. VL, viral load.



Supplemental Figure 2. Detection of SARS-CoV-2 viral load from nasopharyngeal swabs (A), oropharyngeal swabs (B) and sputum (C), categorized by respiratory disease severity. P-values are from χ^2 analysis.

Supplemental Table 1. Logistic regression analysis of association of viral load with risk of death

Specimen Type	Variable type¹	Odds Ratio	P-value
Plasma	Categorical	5.5	0.02
Nasopharyngeal	Categorical	2.4	0.25
Oropharyngeal	Categorical	3.5	0.27
Sputum ²	Categorical	-	-
Plasma	Continuous	2.4	0.04
Nasopharyngeal	Continuous	1.4	0.09
Oropharyngeal	Continuous	2.1	0.02
Sputum	Continuous	2.8	0.048

¹Categorical refers to analysis of viral loads as detectable or not detectable

²There were no deaths in participants with undetectable sputum viral loads